Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
BioMarin Pharmaceutical
BioMarin Pharmaceutical
Activities:
Distribution
Manufacturing
Pharmaceutical
X
LinkedIn
Trending Articles
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Actylis and Novo Nordisk Pharmatech partner for the distribution of benzalkonium chloride
The two companies aim to expand the distribution of benzalkonium chloride within Europe
Upperton opens novel development and GMP manufacturing facility
The novel 50,000 sqft development and GMP manufacturing facility in Nottingham contains ten GMP manufacturing suites, quality control laboratories and formulation development...
Astellas begins construction of manufacturing site in Tralee
600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Policy vacuum risks UK becoming a medicines supply backwater
The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Ingredients
Therapeutic: vosoritide for achondroplasia
Achondroplasia is the most common form of skeletal dysplasia, yet no effective therapies exist
Finance
Merck returns rights to metabolism drug Kuvan to BioMarin
Merck will receive an upfront payment of €340m plus €185m in additional milestones
You need to be a subscriber to read this article.
Click here
to find out more.
Regulatory
New NCEs focus on cancer and orphan diseases
The number of NCEs approved in Europe increased again in 2014, with the spotlight on cancer drugs and treatments for unmet medical needs. Dr Sarah Houlton reviews the new entrants
Regulatory
Prosensa appoints Head of Global Regulatory Affairs
Dr Larry Bell will oversee global regulatory activities at the company
Regulatory
A lucrative niche in orphan diseases?
The number of potential blockbuster drugs is in decline so many Big Pharma companies are looking to rare diseases to fill their pipelines because low sales volumes can be balanced out by premium prices.
Regulatory
US FDA approves BioMarin plant expansion
Doubles current capacity at Novato, CA
Subscribe now